IAD Index of Academic Documents
  • Home Page
  • About
    • About Izmir Academy Association
    • About IAD Index
    • IAD Team
    • IAD Logos and Links
    • Policies
    • Contact
  • Submit A Journal
  • Submit A Conference
  • Submit Paper/Book
    • Submit a Preprint
    • Submit a Book
  • Contact
  • Acta Medica Alanya
  • Cilt: 9 Sayı: 1
  • Effectiveness of Intrauterine Levonorgesterel-Releasing Device in the Treatment of Endometrial Hyper...

Effectiveness of Intrauterine Levonorgesterel-Releasing Device in the Treatment of Endometrial Hyperplasia in Obese Patients

Authors : Sezin Ateş, Işıl Çiçekdağı
Pages : 36-41
View : 41 | Download : 93
Publication Date : 2025-04-01
Article Type : Research Paper
Abstract :Aim: Endometrial hyperplasia (EH) is a precursor lesion of endometrial adenocarcinoma, the most common gynecological malignancy in women. Endometrial hyperplasias divided in two groups: non-atypical hyperplasia and atypical hyperplasia. The most commonly used treatment approach is progestin therapy for non-atypical hyperplasias. In this study, we aimed to compare the regression outcomes in control biopsies between obese and non obese patients diagnosed with non-atypical endometrial hyperplasia who were treated with an LNG-IUD and followed up in our clinic. Methods: This study conducted was patients were diagnosed with non-atypical endometrial hyperplasia via endometrial biopsy and treated with intrauterine levonorgestrel. Patient data were reviewed retrospectively. Patients were divided into two groups based on BMI: obese and non-obese. İn regression and treatment success were assessed between control endometrial biopsies taken at 6 and 12 months in the obese and non-obese groups. Results: A total of 110 patients were included in the study who were categorized into two groups according to BMI as obese and non-obese. Data of 32 patients in the obese patient group and 78 patients in the non-obese patient group were examined. In obese patients, the regression rate at the 6th month was 62.5%, and the regression rate at the 12th month was 90.6%. In non-obese patients, the regression rate at the 6th month was 96%, and the regression rate at the 12th month was 97.4%. In the obese patient group, both the 6th-month regression rate and the 12th-month regression rate were statistically significantly lower compared to the non-obese patient group. (p < 0.05). Conclusions: Obesity negatively affects the response to progesterone treatment and that regression rates decrease as BMI increases.
Keywords : Endometrial hiperplazi, Obezite, Progestin, Levo-norgestrel

ORIGINAL ARTICLE URL
VIEW PAPER (PDF)

* There may have been changes in the journal, article,conference, book, preprint etc. informations. Therefore, it would be appropriate to follow the information on the official page of the source. The information here is shared for informational purposes. IAD is not responsible for incorrect or missing information.


Index of Academic Documents
İzmir Academy Association
CopyRight © 2023-2025